Health Care Cost

Access and affordability are among the top priorities in health care for Americans who participated in the survey.

Abandoning efforts to reform payment for cell and gene therapies for Medicaid beneficiaries could allow ongoing access barriers to persist, said Adam Colborn, JD, of AMCP.

Within the past week, news has emerged from the Trump administration, from the HHS secretary confirmation hearings to retracted FDA guidelines on diversity in clinical trials.

New research highlights the significant health care resource utilization burden of generalized pustular psoriasis (GPP), revealing higher hospitalizations and costs among patients experiencing flares.

With historical data showing migraine to be underdiagnosed and undertreated, new guidance from the American College of Physicians (ACP) encompasses 3 recommendations on treating episodic migraine in adult patients in the outpatient setting.

A polypill for preventing cardiovascular disease has the potential to address health inequities and expand health care access for low-income populations.

This week, Robert F. Kennedy Jr sat before the Senate for 2 separate hearings, to decide the fate of his confirmation as secretary of HHS.

Adam Colborn, JD, of AMCP, discusses the complexities of drug pricing and what policymakers must consider in efforts to reduce prices and increase access.

Adam Colborn, JD, of AMCP, discussed how President Trump's rescission of several Biden-era executive orders may impact Medicaid and Medicare initiatives.

Sen. Bill Cassidy, MD, (R, Louisiana) holds a key vote on Robert F. Kennedy Jr's HHS Secretary confirmation. When Cassidy asked for a strategy on Medicare and Medicaid, Kennedy could not provide one.

According to the CDC, frequent consumption of sugary drinks is linked to adverse health outcomes that include obesity, type 2 diabetes, heart disease, nonalcoholic liver disease, and gout.

Amazon Pharmacy's RxPass program shows promise in boosting medication adherence and reducing costs, according to a study.

Highlights from last week include President Trump's executive orders, the FDA approval of esketamine nasal spray for depression, mental health access through Medicaid Managed Care, the impact of travel time on surgical outcomes, and life expectancy disparities.

For this study, outcomes were compared between 2 groups of patients with myasthenia gravis: those who developed exacerbations and those who did not experience exacerbations.

Samsung Bioepis' Q1 2025 report shows oncology, ophthalmology, and pegfilgrastim biosimilars have gained significant market share, while immunology, filgrastim, epoetin alfa, and insulin glargine biosimilars have grown more slowly.

President Donald Trump's initial executive orders target previous efforts to reduce health care costs, pandemic preparedness, and international partnerships, showing a stark contrast to the Biden administration.

Experts suggest that most Americans will not experience immediate changes in their out-of-pocket health care expenses.

Attorneys General from several districts have come together in a lawsuit seeking damages from Walgreens for allegedly knowingly filling opioid prescriptions that lacked a genuine medical purpose.

Despite the availability of several noninvasive tests for colorectal cancer, prioritizing blood-based tests may result in higher costs and worse population-level outcomes.

A report from the Federal Trade Commission (FTC) has determined that pharmacy benefit managers (PBMs) are linked to significant cost increases for cancer, HIV, and other critical specialty drugs.

There is limited awareness and utilization of supplemental benefits among Medicare Advantage beneficiaries, with cost-sharing and out-of-pocket spending playing key roles, a new study has found.

The health equity impact of the polypill is significant; by effectively controlling cardiovascular disease (CVD) risk factors in populations with limited health care access, there's potential to reduce income- and race-related health disparities.

ACA enrollment rate hits a milestone, though IRA subsidies may not extend beyond 2025; network adequacy standards fail to translate into efficient access to mental health care for Medicaid enrollees; research examines racial disparities in postpartum hypertension and vaccine uptake.

The pharmaceutical landscape enters 2025 with a mix of challenges and opportunities, with the potential to shape the future of drug access and affordability for patients across the nation.

Acts of discrimination, including subtle microaggressions, during pregnancy and childbirth contribute to higher maternal mortality rates, especially among Black women, and are linked to increased postpartum blood pressure, highlighting the need for improved health care interventions and racial equity in maternity care.

Record numbers have enrolled in Affordable Care Act (ACA) coverage as open enrollment continues through January 15, 2025.

Data pulled from the impact of Clinical Resource Hubs (CRHs) demonstrate the benefits these programs provide to veterans who may be experiencing gaps in care.

Cochair of our recent Institute for Value-Based Medicine® event hosted with NYU Langone Health, Oscar B. Lahoud, MD, speaks on his hoped-for top health care priorities under the incoming administration.

Robin Glasco, MBA, Spencer Stuart, examines the crucial role of data in addressing urgent challenges in health care while inherent and systemic biases coexist, complicating efforts to achieve equity.

How does age, sex, comorbidity, and screening history influence the cost-effectiveness of continuing colorectal cancer (CRC) screening in older adults?